Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation

References

• PhillipsSJWhisnantJPO’FallonWMFryeRLPrevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, MinnesotaMayo Clin Proc19906533443592248634
   PubMed Web of Science ®Google Scholar
• GoASHylekEMPhillipsKAPrevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) StudyJAMA2001285182370237511343485
   PubMed Web of Science ®Google Scholar
• KannelWBBenjaminEJStatus of the epidemiology of atrial fibrillationMed Clin North Am20089211740ix18060995
   PubMed Web of Science ®Google Scholar
• MiyasakaYBarnesMEGershBJSecular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalenceCirculation2006114211912516818816
   PubMed Web of Science ®Google Scholar
• KannelWBWolfPABenjaminEJLevyDPrevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimatesAm J Cardiol1998828A2N9N
   PubMed Web of Science ®Google Scholar
• PsatyBMManolioTAKullerLHIncidence of and risk factors for atrial fibrillation in older adultsCirculation1997967245524619337224
   PubMed Web of Science ®Google Scholar
• NovoGGuttillaDFazioGCooperDNovoSThe role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBSBr J Clin Pharmacol200866334535118782141
   PubMed Web of Science ®Google Scholar
• FusterVRydenLECannomDSACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation)Eur Heart J200627161979203016885201
   PubMedGoogle Scholar
• BenjaminEJWolfPAD’AgostinoRBSilbershatzHKannelWBLevyDImpact of atrial fibrillation on the risk of death: the Framingham Heart StudyCirculation199898109469529737513
   PubMed Web of Science ®Google Scholar
• HartRGHalperinJLAtrial fibrillation and stroke: concepts and controversiesStroke200132380380811239205
   PubMed Web of Science ®Google Scholar
• WolfPAAbbottRDKannelWBAtrial fibrillation as an independent risk factor for stroke: the Framingham StudyStroke19912289839881866765
   PubMed Web of Science ®Google Scholar
• AllessieMAAtrial electrophysiologic remodeling: another vicious circle?J Cardiovasc Electrophysiol1998912137813939869538
   PubMedGoogle Scholar
• AusmaJvan der VeldenHMLendersMHReverse structural and gap-junctional remodeling after prolonged atrial fibrillation in the goatCirculation2003107152051205812681996
   PubMed Web of Science ®Google Scholar
• HeidbuchelHA paradigm shift in treatment for atrial fibrillation: from electrical to structural therapy?Eur Heart J200324232077207814643265
   PubMedGoogle Scholar
• HobbsWJFynnSToddDMWolfsonPGallowayMGarrattCJReversal of atrial electrical remodeling after cardioversion of persistent atrial fibrillation in humansCirculation2000101101145115110715261
   PubMedGoogle Scholar
• NattelSShiroshita-TakeshitaACardinSPelletierPMechanisms of atrial remodeling and clinical relevanceCurr Opin Cardiol2005201212515596955
   PubMed Web of Science ®Google Scholar
• SanfilippoAJAbascalVMSheehanMAtrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic studyCirculation19908237927972144217
   PubMed Web of Science ®Google Scholar
• ThijssenVLAusmaJLiuGSAllessieMAvan EysGJBorgersMStructural changes of atrial myocardium during chronic atrial fibrillationCardiovasc Pathol200091172810739903
   PubMed Web of Science ®Google Scholar
• AllessieMABoydenPACammAJPathophysiology and prevention of atrial fibrillationCirculation2001103576977711156892
   PubMed Web of Science ®Google Scholar
• MattioliAVVivoliDBastiaEDoppler echocardiographic parameters predictive of recurrence of atrial fibrillation of different etiologic originsJ Ultrasound Med199716106956989323676
   PubMedGoogle Scholar
• VerdecchiaPReboldiGGattobigioRAtrial fibrillation in hypertension: predictors and outcomeHypertension200341221822312574085
   PubMed Web of Science ®Google Scholar
• FreudenbergerRSWilsonACKostisJBComparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM Study)Am J Cardiol2007100224725217631079
   PubMed Web of Science ®Google Scholar
• HohnloserSHKuckKHLilienthalJRhythm or rate control in atrial fibrillation – Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trialLancet200035692441789179411117910
   PubMed Web of Science ®Google Scholar
• PedersenODBaggerHKoberLTorp-PedersenCTrandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunctionCirculation1999100437638010421597
   PubMed Web of Science ®Google Scholar
• VermesETardifJCBourassaMGEnalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trialsCirculation2003107232926293112771010
   PubMed Web of Science ®Google Scholar
• MaggioniAPLatiniRCarsonPEValsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)Am Heart J2005149354855715864246
   PubMed Web of Science ®Google Scholar
• SchmiederREKjeldsenSEJuliusSMcInnesGTZanchettiAHuaTAReduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trialJ Hypertens200826340341118300848
   PubMed Web of Science ®Google Scholar
• WachtellKLehtoMGerdtsEAngiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) studyJ Am Coll Cardiol200545571271915734615
   PubMed Web of Science ®Google Scholar
• WachtellKHornestamBLehtoMCardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) studyJ Am Coll Cardiol200545570571115734614
   PubMed Web of Science ®Google Scholar
• WeberMAJuliusSKjeldsenSEBlood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE TrialLancet200436394262049205115207957
   PubMed Web of Science ®Google Scholar
• SchoonderwoerdBAVan GelderICVan VeldhuisenDJVan Den BergMPCrijnsHJElectrical and structural remodeling: role in the genesis and maintenance of atrial fibrillationProg Cardiovasc Dis200548315316816271942
   PubMedGoogle Scholar
• Van WagonerDRNerbonneJMMolecular basis of electrical remodeling in atrial fibrillationJ Mol Cell Cardiol20003261101111710888261
   PubMed Web of Science ®Google Scholar
• GoetteAArndtMRockenCRegulation of angiotensin II receptor subtypes during atrial fibrillation in humansCirculation2000101232678268110851203
   PubMedGoogle Scholar
• von LewinskiDKockskamperJRubertusSUDirect pro-arrhythmogenic effects of angiotensin II can be suppressed by AT1 receptor blockade in human atrial myocardiumEur J Heart Fail200810121172117618993115
   PubMedGoogle Scholar
• ChaYMRedfieldMMShenWKGershBJAtrial fibrillation and ventricular dysfunction: a vicious electromechanical cycleCirculation2004109232839284315197156
   PubMed Web of Science ®Google Scholar
• FrustaciAChimentiCBellocciFMorganteERussoMAMaseriAHistological substrate of atrial biopsies in patients with lone atrial fibrillationCirculation1997964118011849286947
   PubMed Web of Science ®Google Scholar
• Van GelderICHemelsMEThe progressive nature of atrial fibrillation: a rationale for early restoration and maintenance of sinus rhythmEuropace200681194394916973685
   PubMedGoogle Scholar
• VerheuleSWilsonEEverettTShanbhagSGoldenCOlginJAlterations in atrial electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral regurgitationCirculation2003107202615262212732604
   PubMed Web of Science ®Google Scholar
• WijffelsMCKirchhofCJDorlandRAllessieMAAtrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goatsCirculation1995927195419687671380
   PubMed Web of Science ®Google Scholar
• SchneeJMHsuehWAAngiotensin II, adhesion, and cardiac fibrosisCardiovasc Res200046226426810773230
   PubMedGoogle Scholar
• BrillaCGZhouGMatsubaraLWeberKTCollagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosteroneJ Mol Cell Cardiol19942678098207966349
   PubMedGoogle Scholar
• GoetteAStaackTRockenCIncreased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillationJ Am Coll Cardiol20003561669167710807475
   PubMed Web of Science ®Google Scholar
• LiDFarehSLeungTKNattelSPromotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sortCirculation19991001879510393686
   PubMed Web of Science ®Google Scholar
• LiDShinagawaKPangLEffects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failureCirculation2001104212608261411714658
   PubMed Web of Science ®Google Scholar
• SadoshimaJIzumoSMolecular characterization of angiotensin II – induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtypeCirc Res19937334134238348686
   PubMed Web of Science ®Google Scholar
• BoschRFZengXGrammerJBPopovicKMewisCKuhlkampVIonic mechanisms of electrical remodeling in human atrial fibrillationCardiovasc Res199944112113110615396
   PubMedGoogle Scholar
• BoschRFNattelSCellular electrophysiology of atrial fibrillationCardiovasc Res200254225926912062331
   PubMedGoogle Scholar
• YuWCLeeSHTaiCTReversal of atrial electrical remodeling following cardioversion of long-standing atrial fibrillation in manCardiovasc Res199942247047610533582
   PubMedGoogle Scholar
• YueLFengJGaspoRLiGRWangZNattelSIonic remodeling underlying action potential changes in a canine model of atrial fibrillationCirc Res19978145125259314832
   PubMedGoogle Scholar
• NakashimaHKumagaiKUrataHGondoNIdeishiMArakawaKAngiotensin II antagonist prevents electrical remodeling in atrial fibrillationCirculation2000101222612261710840013
   PubMed Web of Science ®Google Scholar
• AksnesTAFlaaAStrandAKjeldsenSEPrevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failureJ Hypertens2007251152317143167
   PubMedGoogle Scholar
• ShiYDucharmeALiDGaspoRNattelSTardifJCRemodeling of atrial dimensions and emptying function in canine models of atrial fibrillationCardiovasc Res200152221722511684069
   PubMedGoogle Scholar
• ShiYLiDTardifJCNattelSEnalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failureCardiovasc Res200254245646112062350
   PubMed Web of Science ®Google Scholar
• HealeyJSBaranchukACrystalEPrevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysisJ Am Coll Cardiol200545111832183915936615
   PubMed Web of Science ®Google Scholar
• MurrayKTMaceLCYangZNonantiarrhythmic drug therapy for atrial fibrillationHeart Rhythm200743 SupplS88S9017336893
   PubMedGoogle Scholar
• MadridAHBuenoMGRebolloJMUse of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized studyCirculation2002106333133612119249
   PubMed Web of Science ®Google Scholar
• MadridAHMarinIMCervantesCEPrevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockersJ Renin Angiotensin Aldosterone Syst20045311412015526246
   PubMedGoogle Scholar
• Van NoordTCrijnsHJVan Den BergMPVan VeldhuisenDJVan GelderICPretreatment with ACE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillationBMC Cardiovasc Disord200551315667649
   PubMedGoogle Scholar
• ZamanAGKearneyMTSchecterCWorthleySGNolanJAngiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillationAm Heart J2004147582382715131537
   PubMedGoogle Scholar
• CaballeroRDelponEValenzuelaCLongobardoMTamargoJLosartan and its metabolite E3174 modify cardiac delayed rectifier K(+) currentsCirculation2000101101199120510715269
   PubMedGoogle Scholar
• MorenoICaballeroRGonzalezTEffects of irbesartan on cloned potassium channels involved in human cardiac repolarizationJ Pharmacol Exp Ther2003304286287312538844
   PubMedGoogle Scholar
• BoldtASchollAGarbadeJACE-inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillationBasic Res Cardiol2006101326126716382287
   PubMedGoogle Scholar
• KumagaiKNakashimaHUrataHGondoNArakawaKSakuKEffects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillationJ Am Coll Cardiol200341122197220412821247
   PubMedGoogle Scholar
• LiYLiWYangBEffects of Cilazapril on atrial electrical, structural and functional remodeling in atrial fibrillation dogsJ Electrocardiol200740110010617067622
   PubMedGoogle Scholar
• OkazakiHMinaminoTTsukamotoOAngiotensin II type 1 receptor blocker prevents atrial structural remodeling in rats with hypertension induced by chronic nitric oxide inhibitionHypertens Res200629427728416778335
   PubMedGoogle Scholar
• SakabeMFujikiANishidaKEnalapril prevents perpetuation of atrial fibrillation by suppressing atrial fibrosis and over-expression of connexin 43 in a canine model of atrial pacing-induced left ventricular dysfunctionJ Cardiovasc Pharmacol200443685185915167279
   PubMed Web of Science ®Google Scholar
• DucharmeASwedbergKPfefferMAPrevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programAm Heart J20061521869216838426
   PubMed Web of Science ®Google Scholar
• PfefferMASwedbergKGrangerCBEffects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeLancet2003362938675976613678868
   PubMed Web of Science ®Google Scholar
• CohnJNTognoniGA randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failureN Engl J Med2001345231667167511759645
   PubMed Web of Science ®Google Scholar
• MaggioniAPLatiniRCarsonPEValsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)Am Heart J2005149354855715864246
   PubMed Web of Science ®Google Scholar
• LithellHHanssonLSkoogIThe Study of Cognition and Prognosis in the Elderley (SCOPE): principal results of a randomized double-blind intervention trialJ Hypertens200321587588612714861
   PubMed Web of Science ®Google Scholar
• ONTARGET InvestigatorsYusufSTeoKKTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520
   PubMed Web of Science ®Google Scholar
• FogariRZoppiAMugelliniAComparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitusJ Cardiovasc Pharmacol200851321722218356684
   PubMedGoogle Scholar
• FogariRDerosaGFerrariIEffect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillationAm J Hypertens20082191034103918566593
   PubMedGoogle Scholar
• GISSI-AF InvestigatorsDisertoriMatiniRValsartan for prevention of recurrent atrial fibrillationN Engl J Med2009360161606161719369667
   PubMed Web of Science ®Google Scholar
• GrundvoldITveitASmithPSeljeflotIAbdelnoorMArnesenHThe predictive value of transthoracic echocardiographic variables for sinus rhythm maintenance after electrical cardioversion of atrial fibrillation. Results from the CAPRAF study, a prospective, randomized, placebo-controlled studyCardiology20081111303518239389
   PubMedGoogle Scholar
• TveitAGrundvoldIOlufsenMCandesartan in the prevention of relapsing atrial fibrillationInt J Cardiol20071201859117113170
   PubMedGoogle Scholar
• Active Steering Committee, ACTIVE InvestigatorsConnollySRationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular eventsAm Heart J200615161187119316781218
   PubMedGoogle Scholar
• GoetteABreithardtGFetschTAngiotensin II antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial: rationale and study designClin Drug Investig20072710697705
   PubMedGoogle Scholar
• Irbesartan for the Prevention of Atrial Arrhythmias and Cardiac Electrical Remodeling in Patients With Hypertension and Permanent Pacemakers (NCT00225667) [ClinicalTrials.gov Web site]. http://www.clinicaltrials.gov/ct2/show/NCT00225667?term=NCT00225667&rank=1Accessed June 28, 2009
   Google Scholar
• GoASHylekEMPhillipsKAPrevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) StudyJAMA2001285182370237511343485
   PubMed Web of Science ®Google Scholar